We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00180193
First Posted: September 16, 2005
Last Update Posted: August 26, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Advanced Biochemical Compounds GmbH
Information provided by:
Technische Universität Dresden
  Purpose
The purpose of this study is to monitor the amino acid uptake of brain tumors, before and during radiotherapy, with positron emission tomography.

Condition Phase
Brain Tumor Phase 2

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: F-18-OMFD-PET for Radiotherapy Treatment Planning and Evaluation of Early Therapy Response

Further study details as provided by Technische Universität Dresden:

Estimated Enrollment: 40
Study Start Date: December 2003
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
OMFD-PET of all patients after subtotal resection or biopsy of malignant glioma was evaluated.
Criteria

Inclusion Criteria:

  • Brain tumor
  • Radiation therapy indicated
  • Written consent

Exclusion Criteria:

  • Pregnancy
  • Mental impairment
  • Drug/alcohol abuse
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00180193


Locations
Germany
Department of Nuclear Medicine
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Advanced Biochemical Compounds GmbH
Investigators
Principal Investigator: Joerg Kotzerke, MD Department of Nuclear Medicine
  More Information

Responsible Party: Prof. Dr. med. Jörg Kotzerke, Klinik und Poliklinik für Nuklearmedizin
ClinicalTrials.gov Identifier: NCT00180193     History of Changes
Other Study ID Numbers: ABX-OMFD-FU
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: August 26, 2009
Last Verified: August 2009

Keywords provided by Technische Universität Dresden:
Radiotherapy
F-18-OMFD